Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MCS110 + PDR001 in esophageal squamous cell carcinoma
KCT0003631Phase 2Active, not recruiting
- Sponsor
- Yonsei University Health System
- Start
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lacnotuzumab, spartalizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Yonsei University Health System. Started Mar 2020; status: active, not recruiting.
02
Drugs
lacnotuzumabspartalizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on KCT0003631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003631.